English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/191318
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Identification and validation of stage‐associated serum biomarkers in colorectal cancer using MS‐based procedures

AuthorsMarín-Vicente, Consuelo; Mendes, Marta; de los Ríos, Vivian; Fernandez-Aceñero, M. Jesús; Casal, J. Ignacio
KeywordsAPOC3
PRM
THBS1
Colorectal cancer
Serum biomarkers
Issue Date9-Sep-2019
PublisherJohn Wiley & Sons
CitationProteomics Clin Appl e1900052 (2019)
AbstractPURPOSE:Successful prevention of colorectal cancer (CRC) would benefit from a rapid serum screening for early detection. Here, a novel strategy for CRC biomarker discovery and validation exclusively based on MS procedures is reported.
EXPERIMENTAL DESIGN:Identification of CRC serum biomarkers is initially made using label-free quantification on pooled serum samples from different CRC stages followed by two consecutive steps of targeted parallel reaction monitoring assays in different serum cohorts. Relevance of different protein depletion and peptide fractionation extent is investigated. Absolute quantification of a selected peptide is performed as a proof-of-concept.
RESULTS:A total of 945 proteins showed differential abundance in the discovery phase. Based on their statistical significance and relative expression in disease stages, 123 potential biomarkers are selected for a training step. In the final validation step, five peptides belonging to four proteins are consistently quantified in individual CRC serum samples and controls. Different statistical analyses indicate that peptides GWVTDGFSSLK (APOC3) and LCNNPTPQFGGK (THBS1) are candidate biomarkers. Absolute quantification of LCNNPTPQFGGK shows statistical significance for the diagnosis of early respect to late CRC stages.
CONCLUSIONS AND CLINICAL RELEVANCE:Two peptides from APOC3 and THBS1 are validated by PRM as potential biomarkers for non-invasive diagnosis of colorectal cancer.
Description10 p.-5 fig.
Publisher version (URL)https://doi.org/10.1002/prca.201900052
URIhttp://hdl.handle.net/10261/191318
DOI10.1002/prca.201900052
ISSN1862-8346
E-ISSN1862-8354
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
restringido.pdfRestringido20,59 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.